Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593884 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL29775131 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL1002064 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL83474 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL1161605 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL674106 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL3216510 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL5635861 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL163842 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL29777394 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132918-A1 | NEW ANTI-MALARIAL AGENTS | University Of Kentucky Research Foundation (US) | 2023-02-15 | — | — | EP | claimed |
| CN-112679405-A | Preparation method of (S) -7-oxa-2-azaspiro [4.5] decane derivative | 南京富润凯德生物医药有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-112625776-A | Graphene compound for lubricating oil additive and preparation method and application thereof | 中国石油化工股份有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-110151952-A | The preparation method of sow aphrodisiac powder | 浙江大飞龙动物保健品股份有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-110150482-A | A kind of sow aphrodisiac powder | 浙江大飞龙动物保健品股份有限公司 | 2019-08-23 | — | — | CN | claimed |
| US-10227305-B2 | Process for preparing indacaterol and salts thereof | REDDY, G. Pratap (IN) | 2019-03-12 | — | — | US | claimed |
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | REDDY, G. Pratap (IN) | 2018-08-28 | — | — | US | claimed |
| US-20180215714-A1 | A Process for Preparing Indacaterol and Salts Thereof | REDDY, G. Pratap (IN) | 2018-08-02 | — | — | US | claimed |
| CN-107674010-A | The preparation method and detection method of a kind of Ecadotril | 陕西汉江药业集团股份有限公司 | 2018-02-09 | — | — | CN | claimed |
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | claimed |
| US-5489710-A | AMINATION BY MIXING WITH NITRILE SOLVENT, ACIDIFICATION AND HYDROLYZING WITH WATER | MERCK & CO., INC. (US) | 1996-02-06 | — | — | US | claimed |
| WO-1995024375-A1 | REGIOSPECIFIC PROCESS TO MAKE CIS-1-AMINO-2-ALKANOL FROM EPOXIDE | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1995024374-A1 | REGIOSPECIFIC PROCESSES TO MAKE CIS-1-AMINO-2-ALKANOL FROM DIOL OR HALOHYDRIN | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | claimed |
| US-5449830-A | Enzyme inhibitors for protease encoded for HIV | MARCK & CO., INC. (US) | 1995-09-12 | — | — | US | claimed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | claimed |
| US-5420353-A | Protease inhibitors, AIDS | MERCK & CO., INC. (US) | 1995-05-30 | — | — | US | claimed |
| WO-1995008636-A1 | RACEMATE CLEAVAGE OF PRIMARY AND SECONDARY AMINES BY ENZYME-CATALYSED ACYLATION | BASF AKTIENGESELLSCHAFT (DE) | 1995-03-30 | — | — | WO | claimed |
| WO-1995007880-A1 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| EP-0578745-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-01-19 | — | — | EP | claimed |
| WO-1992017490-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES | THE UPJOHN COMPANY (US) | 1992-10-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215714-A1 | A Process for Preparing Indacaterol and Salts Thereof | CYP11B1, CYP4A11, CYP17A1 | ANPEP 1215/4885KDM1A 2778/4885HTR2A 2543/4885 |
| US-10227305-B2 | Process for preparing indacaterol and salts thereof | CYP4A11, HSD17B7, CYP17A1 | ANPEP 1424/4885KDM1A 3079/4885HTR2A 2814/4885 |
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | CYP4A11, CYP11B1, CYP11B2 | ANPEP 3475/4885KDM1A 3424/4885HTR2A 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.